Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Metis Global Partners LLC

Metis Global Partners LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 17.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 119,251 shares of the biopharmaceutical company’s stock after acquiring an additional 17,479 shares during the period. Metis Global Partners LLC’s holdings in Bristol-Myers Squibb were worth $6,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. McClarren Financial Advisors Inc. increased its position in shares of Bristol-Myers Squibb by 532.7% in the 4th quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,582 shares during the period. Institute for Wealth Management LLC. boosted its holdings in Bristol-Myers Squibb by 1.0% in the fourth quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after purchasing an additional 296 shares during the last quarter. Herold Advisors Inc. boosted its holdings in Bristol-Myers Squibb by 3.2% in the third quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after purchasing an additional 1,051 shares during the last quarter. Kestra Private Wealth Services LLC boosted its holdings in Bristol-Myers Squibb by 9.5% in the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock valued at $8,115,000 after purchasing an additional 12,121 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Bristol-Myers Squibb by 0.5% in the third quarter. Signaturefd LLC now owns 105,986 shares of the biopharmaceutical company’s stock valued at $6,151,000 after purchasing an additional 564 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Barclays lowered their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Price Performance

BMY traded up $0.29 on Friday, hitting $43.99. 12,104,489 shares of the company’s stock were exchanged, compared to its average volume of 14,314,010. The firm has a 50-day moving average price of $50.37 and a 200-day moving average price of $50.65. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a market cap of $89.17 billion, a price-to-earnings ratio of -14.19, a P/E/G ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a fifty-two week low of $43.33 and a fifty-two week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were given a dividend of $0.60 per share. The ex-dividend date was Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.46%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.